• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人血管紧张素II 1型(AT(1))受体的配体支持同源性建模:对替米沙坦结合分子决定因素的见解。

Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.

作者信息

Patny Akshay, Desai Prashant V, Avery Mitchell A

机构信息

Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, Mississippi 38677-1848, USA.

出版信息

Proteins. 2006 Dec 1;65(4):824-42. doi: 10.1002/prot.21196.

DOI:10.1002/prot.21196
PMID:17034041
Abstract

Angiotensin II type 1 (AT(1)) receptor belongs to the super-family of G-protein-coupled receptors, and antagonists of the AT(1) receptor are effectively used in the treatment of hypertension. To understand the molecular interactions of these antagonists, such as losartan and telmisartan, with the AT(1) receptor, a homology model of the human AT(1) (hAT(1)) receptor with all connecting loops was constructed from the 2.6 A resolution crystal structure (PDB i.d., 1L9H) of bovine rhodopsin. The initial model generated by MODELLER was subjected to a stepwise ligand-supported model refinement. This protocol involved initial docking of non-peptide AT(1) antagonists in the putative binding site, followed by several rounds of iterative energy minimizations and molecular dynamics simulations. The final model was validated based on its correlation with several structure-activity relationships and site-directed mutagenesis data. The final model was also found to be in agreement with a previously reported AT(1) antagonist pharmacophore model. Docking studies were performed for a series of non-peptide AT(1) receptor antagonists in the active site of the final hAT(1) receptor model. The docking was able to identify key molecular interactions for all the AT(1) antagonists studied. Reasonable correlation was observed between the interaction energy values and the corresponding binding affinities of these ligands, providing further validation for the model. In addition, an extensive unrestrained molecular dynamics simulation showed that the docking-derived bound pose of telmisartan is energetically stable. Knowledge gained from the present studies can be used in structure-based drug design for developing novel ligands for the AT(1) receptor.

摘要

血管紧张素II 1型(AT(1))受体属于G蛋白偶联受体超家族,AT(1)受体拮抗剂可有效用于治疗高血压。为了解这些拮抗剂(如氯沙坦和替米沙坦)与AT(1)受体的分子相互作用,利用牛视紫红质2.6 Å分辨率的晶体结构(蛋白质数据库编号,1L9H)构建了具有所有连接环的人AT(1)(hAT(1))受体同源模型。由MODELLER生成的初始模型经过逐步的配体支持模型优化。该方案包括将非肽类AT(1)拮抗剂初步对接至假定的结合位点,随后进行几轮迭代能量最小化和分子动力学模拟。基于最终模型与几种构效关系和定点诱变数据的相关性对其进行验证。还发现最终模型与先前报道的AT(1)拮抗剂药效团模型一致。在最终的hAT(1)受体模型的活性位点对一系列非肽类AT(1)受体拮抗剂进行对接研究。对接能够确定所研究的所有AT(1)拮抗剂的关键分子相互作用。观察到这些配体的相互作用能值与相应结合亲和力之间存在合理的相关性,为该模型提供了进一步的验证。此外,广泛的无约束分子动力学模拟表明,替米沙坦对接衍生的结合构象在能量上是稳定的。从本研究中获得的知识可用于基于结构的药物设计,以开发新型的AT(1)受体配体。

相似文献

1
Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding.人血管紧张素II 1型(AT(1))受体的配体支持同源性建模:对替米沙坦结合分子决定因素的见解。
Proteins. 2006 Dec 1;65(4):824-42. doi: 10.1002/prot.21196.
2
Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.人尿紧张素II受体的三维模型:人尿紧张素II和非肽拮抗剂在结合位点的对接以及与拮抗剂药效团模型的比较
Proteins. 2008 Oct;73(1):173-84. doi: 10.1002/prot.22050.
3
Ligand binding determinants for angiotensin II type 1 receptor from computer simulations.计算机模拟血管紧张素 II 型 1 受体的配体结合决定因素。
J Chem Inf Model. 2013 Nov 25;53(11):2874-83. doi: 10.1021/ci400400m. Epub 2013 Oct 25.
4
Structural determinants of subtype selectivity and functional activity of angiotensin II receptors.血管紧张素 II 受体亚型选择性和功能活性的结构决定因素。
Bioorg Med Chem Lett. 2016 Feb 15;26(4):1355-9. doi: 10.1016/j.bmcl.2015.10.084. Epub 2015 Oct 29.
5
Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor.替米沙坦独特的“δ 键锁”结构使其与血管紧张素 II 型 1 受体具有最强的结合亲和力。
Biochem Biophys Res Commun. 2011 Jan 7;404(1):434-7. doi: 10.1016/j.bbrc.2010.11.139. Epub 2010 Dec 3.
6
Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling.通过分子模拟研究缬沙坦、坎地沙坦和氯沙坦与血管紧张素II受体1亚型的结合位点。
Life Sci. 2009 Jul 17;85(3-4):136-40. doi: 10.1016/j.lfs.2009.05.001. Epub 2009 May 14.
7
Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis.非肽类AT1拮抗剂新结合取向的提议:同源建模、对接及三维定量构效关系分析
J Med Chem. 2006 Jul 13;49(14):4305-16. doi: 10.1021/jm060338p.
8
Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.组胺H3受体拮抗剂复合物的三维模型及其药效基团。
J Mol Graph Model. 2006 May;24(6):456-64. doi: 10.1016/j.jmgm.2005.10.005. Epub 2005 Dec 28.
9
Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.奥美沙坦与替米沙坦和人血管紧张素II 1型受体之间相互作用的分子特征
Br J Pharmacol. 2007 Aug;151(7):952-62. doi: 10.1038/sj.bjp.0707323. Epub 2007 Jun 18.
10
First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.CCR3 受体拮抗剂的首个药效基团模型及其同源模建辅助的逐步虚拟筛选。
Chem Biol Drug Des. 2011 May;77(5):373-87. doi: 10.1111/j.1747-0285.2011.01088.x. Epub 2011 Mar 1.

引用本文的文献

1
Prediction of the Human EP1 Receptor Binding Site by Homology Modeling and Molecular Dynamics Simulation.通过同源建模和分子动力学模拟预测人类EP1受体结合位点
Sci Pharm. 2011 Oct-Dec;79(4):793-816. doi: 10.3797/scipharm.1106-24. Epub 2011 Aug 7.
2
Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.人源甲酰肽受体 1 的 2-(苯并咪唑-2-基硫代)-N-苯基乙酰胺衍生小分子激动剂的分子对接。
J Mol Model. 2012 Jun;18(6):2831-43. doi: 10.1007/s00894-011-1307-x. Epub 2011 Nov 30.
3
Template-based protein modeling: recent methodological advances.
基于模板的蛋白质建模:最新方法进展。
Curr Top Med Chem. 2010;10(1):84-94. doi: 10.2174/156802610790232314.
4
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.14 - O - 杂环取代的纳曲酮衍生物作为非肽类μ阿片受体选择性拮抗剂:设计、合成及生物学研究
Bioorg Med Chem Lett. 2009 Mar 15;19(6):1825-9. doi: 10.1016/j.bmcl.2008.12.093. Epub 2008 Dec 29.
5
Comparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.在CCR5同源模型中,将阿尼巴明作为首个天然产物CCR5拮抗剂的比较对接研究。
J Chem Inf Model. 2009 Jan;49(1):120-32. doi: 10.1021/ci800356a.
6
Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators.识别β₂肾上腺素能受体的构象变化,以实现对配体/受体相互作用的准确预测并筛选G蛋白偶联受体调节剂。
J Comput Aided Mol Des. 2009 May;23(5):273-88. doi: 10.1007/s10822-008-9257-9. Epub 2009 Jan 16.